Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs Neurocrine Biosciences Inc — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.52, while Neurocrine Biosciences Inc trades at $170.05 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.
| BIL | NBIX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $91.77 | $180.55 |
52-Week Low | $91.27 | $123.10 |
Market Cap | — | $17.30B |
Enterprise Value | — | $16.39B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
